Mobile

A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002738-36

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare the duration of survival between the two treatment arms.

Critère d'inclusion

  • Metastatic Hormone-Refractory Prostate Cancer

Liens